Recomendaciones SER sobre la utilización de fármacos biológicos en el síndrome de Sjögren primario

Sánchez, J. L. Andréu; Castro, M. Fernández; Fontecha, Petra Díaz del Campo; Corominas, Hèctor; García, Francisco Javier Narváez; Rúa-Figueroa, Íñigo; Hernández, Miguel Ángel Abad; Rivas, María Noelia Álvarez; Montes, Javier del Pino; Hernández, Félix Manuel Francisco; Pedraza, María Ángeles Gantes; Greco, Martin; Hernández, María Vanesa; Compán, M. V. Navarro; Solarte, Juan Alberto Paz; Bueno, Fredeswinda Isabel Romero; Park, Hye-Sang; Mascaró, Francisca Sivera

doi:10.1016/j.reuma.2018.10.014

Cited by 6 publications

(1 citation statement)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RTX has been approved by the EMA and FDA for the treatment of lymphoproliferative syndromes, rheumatoid arthritis, ANCA-associated vasculitis and pemphigus vulgaris. Moreover, RTX treatment may be considered in organ-threatening, refractory systemic lupus erythematosus [32] and in refractory severe extra-glandular manifestations in patients with primary Sjögren's syndrome [33,34].…”

Section: Discussionmentioning

confidence: 99%

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review

Atienza‐Mateo

Remuzgo‐Martínez

Prieto-Peña

et al. 2020

JCM

View full text Add to dashboard Cite

In the present study, we aimed to report our experience with rituximab (RTX) in the treatment of patients with ILD associated with AD (AD-ILD) at a single center. For this purpose, clinical characteristics, radiological findings, and pulmonary function tests (PFTs) of RTX-treated AD-ILD-patients seen from May 2016 until March 2020 at a referral center for individuals with ILD were retrospectively reviewed. Additionally, an updated literature review was conducted. A total of 26 patients (mean age 58.3 ± 11.1 years at ILD diagnosis) was included. The most common ADs related to ILD were systemic sclerosis, idiopathic inflammatory myositis (including anti-synthetase syndrome) and rheumatoid arthritis. Non-specific interstitial pneumonia (n = 12) and usual interstitial pneumonia (n = 11) were the predominant radiological patterns. The sustained improvement in PFTs was observed from the start of RTX, with a statistically significant increase in DLCO from basal to one year after RTX (mean + 4.2%, p = 0.024). Overall, there were no differences when comparing PFT outcome according to the radiological pattern or the specific type of AD. In conclusion, RTX constitutes a good therapeutic option to preserve lung function in patients with AD-ILD, regardless of the radiological pattern or the underlying AD.

show abstract

Section: Discussionmentioning

confidence: 99%